Company / PP&E (Net)
United Therapeutics PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.7B
FY2025
5-year range
$780.9M / $1.7B
FY2021-FY2025
Trend
+41.5%
vs FY2024
Sector context
#14 of 193
Health Care
What the data says
Among 193 Health Care companies, United Therapeutics is in the top 7% for pp&e (net). PP&E (Net) has increased for 5 consecutive years, from $732M in FY2020 to $1.7B in FY2025.
Based on SEC 10-K filings.
$1.7B in FY2025 with a 5-year CAGR of +18.8%. Top quartile in the Health Care sector.
Improved from $1.0B to $1.7B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +26.2%
- 5-Year CAGR
- +18.8%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 193This company $1.7B Sector average $777.6M
▼
+122.4% above sector average
Key checks
Key Insights
- United Therapeutics's pp&e (net) has grown for 5 consecutive years.
- 5-year CAGR of +18.8%, indicating consistent growth.
- In FY2025, pp&e (net) increased 41.5% year-over-year.
- Ranks #14 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.7B | +41.5% |
| FY2024 | $1.2B | +16.9% |
| FY2023 | $1.0B | +21.3% |
| FY2022 | $861.5M | +10.3% |
| FY2021 | $780.9M | +6.7% |
| FY2020 | $731.6M | -0.9% |
| FY2019 | $738.5M | +5.5% |
| FY2018 | $699.7M | +43.0% |
| FY2017 | $489.3M | +0.0% |
| FY2016 | $489.3M | -1.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026